Lana Zhovtis Ryerson, MD
Neurology · Neptune, NJNPI 1831344308
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $38,078 of the $55,952 with a category attached, or 68.1%. 18 manufacturers reported payments, led by Biogen at 42.4% of the total. Reporting peaked in 2023 at $12,902 and has fallen 89.3% since, to $1,381 in 2025. Among neurology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 245 payments — averaging $228.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$24K
- Genentech USA, Inc.$12K
- Sanofi$11K
- Novartis$6K
- Genentech, Inc.$1K
- TG Therapeutics, Inc.$878
- plus $1K from 12 others
Across 97 payments — averaging $12,809 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$763K
- Novartis$214K
- Genentech, Inc.$139K
- TG Therapeutics, Inc.$49K
- Roche Products Limited$45K
- Bristol Myers Squibb$20K
- plus $12K from 1 others
What the payments were for
- Consulting fees$38,07868%
- Speaking & faculty fees$10,48619%
- Travel & lodging$1,6633%
- Food & beverage$5,61410%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 49 | $23,735 |
| Genentech USA, Inc. | 29 | $12,343 |
| Sanofi | 13 | $11,061 |
| Novartis | 36 | $5,671 |
| Genentech, Inc. | 3 | $1,091 |
| TG Therapeutics, Inc. | 29 | $878 |
| Johnson & Johnson | 38 | $284 |
| Amgen(2 entities) | 10 | $179 |
| EMD Serono, Inc. | 5 | $173 |
| AstraZeneca | 9 | $161 |
| Bristol Myers Squibb | 9 | $136 |
| ANI Pharmaceuticals, Inc. | 4 | $65 |
| Vanda Pharmaceuticals Inc. | 4 | $63 |
| Acorda Therapeutics, Inc | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| UCB, Inc. | 1 | $16 |
| Banner Life Sciences, LLC | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,952 in reported general payments places this provider in the 90th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AubagioTeriflunomide | 29 | $317,261 |
| ZeposiaOzanimod Hydrochloride | 28 | $245,640 |
| Kesimpta PenOfatumumab | 19 | $187,823 |
| MayzentSiponimod | 15 | $120,025 |
| VumerityDiroximel Fumarate | 12 | $103,831 |
| Dalfampridine ErDalfampridine | 31 | $16,998 |
| Teriflunomide | 12 | $11,164 |
| Modafinil | 30 | $3,460 |
| Dimethyl Fumarate | 12 | $2,997 |
| Baclofen | 90 | $2,722 |
| Gabapentin | 67 | $1,584 |
| Pregabalin | 48 | $1,553 |
| Oxcarbazepine | 19 | $857 |
| Oxybutynin Chloride ErOxybutynin Chloride | 27 | $582 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 19 | $540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiAubagio | $11,061 | $317,26129 claims |
| NovartisMayzent | $5,671 | $120,02515 claims |
| BiogenVumerity | $23,735 | $103,83112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 521 neurology providers in New Jersey.
Other neurology in Neptune
- David DuncanNeptune$130K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
- Mario VukicHackensack$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.